基因测试在心血管疾病中的应用
Alexandra Smirnova1, Mario Urtis, Eloisa Arbustini
1Centre for Inherited Cardiovascular Diseases, Department of Clinical and Experimental Research, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Current opinion in cardiology
|February 24, 2026
概括
由于越来越多的遗传发现,对心血管疾病 (CVD) 的基因检测至关重要. 本综述涵盖了遗传性心血管疾病类型,测试,局限性和未来更好的诊断方向.
科学领域:
- 心血管遗传学 心血管遗传学
- 医学基因组学 医学基因组学
- 疾病病理生理学病理生理学
背景情况:
- 越来越多地确定了许多心血管疾病 (CVD) 的遗传基础.
- 这导致了对遗传测试的临床需求大幅增加.
- 对遗传性心血管疾病的认识推动了表型,成像和功能研究的进步.
研究的目的:
- 审查遗传性心血管疾病的主要组.
- 总结目前对心血管疾病的基因测试策略.
- 讨论诊断准确性的局限性和未来前景.
主要方法:
- 关于遗传性心血管疾病的综合文献综述.
- 对当前遗传检测方法及其局限性的分析.
- 探索心血管遗传学的未来方向.
主要成果:
- 门德尔心血管疾病包括心肌病变,心律失常,动脉病变等.
- 线粒体疾病也存在与心血管参与.
- 基因测试旨在提供"全合一"的解决方案,提高可访问性.
结论:
- 关键的挑战包括技术限制,结果解释和测试完整性.
- 多学科方法和技术创新是必不可少的.
- 未来的发展优先提高心血管遗传学的诊断准确性.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Genome-wide Association Studies-GWAS
15.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.9K
Principles of Pharmacogenetics: Types of Genetic Variants
54
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
54
Coronary Artery Disease I: Introduction
1.3K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Genetic Screens
5.8K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
57
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57


